Mongolia
Support for Vaccine: Inactivated Polio Virus
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Mongolia
3. Date of Decision Letter: 07/06/2019
4. Date of the Partnership Framework Agreement: 7/Apr/15
5. Programme title: New Vaccine Support (NVS), Inactivated Polio Virus, Routine
6. Programme type: Inactivated Polio Virus
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID
8. Programme Duration: 2015-2019
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>195,153</td>
<td>66,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>261,153</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant

<table>
<thead>
<tr>
<th>Approval</th>
<th>Year</th>
<th>Grant Number</th>
<th>Amount (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>15-MNG-08h-Y</td>
<td>100,000</td>
</tr>
</tbody>
</table>

11. Product switch grant

Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds</th>
<th>2015-2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td></td>
<td>22,100</td>
<td>-</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>195,153</td>
<td>66,000</td>
<td>-</td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

1 This is the entire duration of the Programme.
2 This is the total amount endorsed by Gavi for the entire duration of the Programme.
3 This is the total amount approved by Gavi.
15. Co-financing obligations:

Not applicable

Gavi’s usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

<table>
<thead>
<tr>
<th>Information Submitted</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td>31 March 2019 15 May 2019</td>
</tr>
</tbody>
</table>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
7 June 2019